[go: up one dir, main page]

WO1997017099A1 - Catheter a ballonnet pour l'application de medicaments - Google Patents

Catheter a ballonnet pour l'application de medicaments Download PDF

Info

Publication number
WO1997017099A1
WO1997017099A1 PCT/US1996/017434 US9617434W WO9717099A1 WO 1997017099 A1 WO1997017099 A1 WO 1997017099A1 US 9617434 W US9617434 W US 9617434W WO 9717099 A1 WO9717099 A1 WO 9717099A1
Authority
WO
WIPO (PCT)
Prior art keywords
balloon
ofthe
catheter
lumen
collars
Prior art date
Application number
PCT/US1996/017434
Other languages
English (en)
Inventor
Christine D. Enger
Original Assignee
C.R. Bard, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by C.R. Bard, Inc. filed Critical C.R. Bard, Inc.
Publication of WO1997017099A1 publication Critical patent/WO1997017099A1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M25/00—Catheters; Hollow probes
    • A61M25/10—Balloon catheters
    • A61M25/1002—Balloon catheters characterised by balloon shape
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M25/00—Catheters; Hollow probes
    • A61M25/0043—Catheters; Hollow probes characterised by structural features
    • A61M2025/0057—Catheters delivering medicament other than through a conventional lumen, e.g. porous walls or hydrogel coatings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M25/00—Catheters; Hollow probes
    • A61M25/10—Balloon catheters
    • A61M2025/1043—Balloon catheters with special features or adapted for special applications
    • A61M2025/105—Balloon catheters with special features or adapted for special applications having a balloon suitable for drug delivery, e.g. by using holes for delivery, drug coating or membranes

Definitions

  • the invention relates to catheter techniques for localized treatment, with medicine, drugs, or the like, of a blood vessel or other body organ having a catheter-receptive lumen.
  • a body organ, blood vessel or the like In the treatment of various diseases, it is often desirable to treat a body organ, blood vessel or the like, with medicine or drugs in a high concentration.
  • the systemic application of a sufficiently high dose to treat the organ may flood the body with dangerously high levels ofthe medicament.
  • a relatively high rate of restenosis (ofthe order of 30%) after performing the initial angioplasty. It has been reported that a significant contributing factor to restenosis may be smooth muscle cell proliferation ofthe artery wall.
  • the catheter shown in Wolinsky includes a shaft having a balloon secured near its distal end.
  • the balloon has a central porous region and non-porous end regions.
  • the diameter of the artery-contacting portion ofthe balloon is uniform, including both the porous central region and the non-porous regions.
  • Another balloon catheter design tends to "bathe" the arterial wall with medicine at relatively low pressures as embodied, for example, in U.S. Patent No. 4,636,195 (Wolinsky).
  • the catheter shown in the Wolinsky ' 195 patent has two independent, longitudinally spaced balloons mounted on the distal region ofthe catheter shaft. Each ofthe balloons provides a substantial fluid seal against the arterial lumen to substantially seal off a specified region ofthe artery.
  • the balloons are in communication with an inflation lumen which is dedicated solely to inflating the two balloons.
  • a second lumen for fluid infusion also is provided through the catheter shaft and leads to a relatively large infusion hole between the balloons.
  • the balloons When in use, the balloons are inflated and medication or other fluid is forced under pressure through the infusion lumen to the relatively large infusion hole. Any blood that might be trapped between the balloons and the artery should leak out of that region since the inflation ofthe sealing balloons can be controlled and can be expected to permit some leakage. A reservoir of fluid forms between the catheter and the arterial wall, thus bathing the treated area. Since this catheter requires at least two lumens plus a third guidewire lumen, it necessarily appears that the overall diameter ofthe catheter is relatively large, thus limiting the catheter's use to larger diameter arteries.
  • FIG. 7 of PCT International Application No. PCT US91/04288 discloses a balloon catheter having a single balloon mounted near its distal end.
  • the balloon has two lobes that are inflatable by a single lumen, and a drug supply lumen that extends along the side ofthe catheter shaft and through one ofthe lobes, terminating at a single, relatively large infusion hole.
  • the catheter has a relatively narrow central region between the lobes that appears to have a diameter of just larger than the shaft ofthe catheter. This narrow central region could create a significant resistance in deflating the distal lobe, thus potentially complicating removal ofthe catheter from the artery.
  • the Shapland balloon catheter requires at least three lumens (similar to the catheter shown in the Wolinsky ' 195 patent), thus making it difficult to inco ⁇ orate into small diameter catheters. It is therefore among the general objects ofthe invention to provide an improved method and low profile apparatus for delivering high concentrations of medications to a localized area of a wide range of diameters of body lumens, and to apply such medications under lower pressures while minimizing device contact with the arterial walls and associated arterial trauma.
  • the invention involves a balloon catheter having a flexible cylindrical balloon at its distal end for delivering a fluid to a localized area of a body lumen.
  • the balloon may be considered as being shaped to define two collars, a central region between the collars, and a plurality of regularly spaced minute perforations in the central region, through which medication may flow under conditions that reduce the tendency to jet yet which bathes the luminal surface and reduces the risk of trauma.
  • a flow area defined by the perforations in the balloon is selected to provide a relatively low flow rate (typically on the order of a few cubic centimeters per minute) through the balloon wall. The flow rate should not be large enough so that the medication jets from the balloon when a maximum recommended pressure is applied to the interior ofthe balloon.
  • the flow area ofthe perforation is sufficiently small enough so that it does not adversely impair the collapsing ofthe balloon upon aspiration, and also so that it prevents substantial medicine leakage through the perforations as the balloon is being inflated.
  • the diameter ofthe central region ofthe balloon is slightly less than the diameter ofthe collars to reduce the risk of jetting while effecting a low pressure bathing of the vessel wall and maintaining a large flow area through the entire balloon to facilitate rapid deflation.
  • the balloon interior communicates with an inflation lumen that extends through the shaft of the catheter from a fitting at the proximal end ofthe catheter. The fitting is used for communicating the inflation lumen with a syringe or other pressure infusion device.
  • the catheter Prior to use, the catheter is selected with respect to the body lumen to be treated so that the inflated central region ofthe balloon will not be in contact with the body lumen, and the two collars ofthe balloon will be in substantial sealing contact with the body lumen.
  • the substantial seal between the body lumen and the two collars enables fluids to slowly leak around the edges ofthe collars.
  • the collars When the balloon is inflated within the body lumen, the collars will press firmly against the surface ofthe body lumen, and the central region ofthe balloon will define a shallow annular reservoir between the balloon and the body lumen. Only a portion ofthe surface area ofthe balloon is therefore in contact with the arterial wall, thus minimizing arterial trauma.
  • the balloon has been inflated with the medication solution, continued pressure applied to the interior ofthe balloon by the pressure infusion device will cause the medication to slowly flow through the perforations in the central region ofthe balloon.
  • the medication will consequently fill the reservoir, thus bathing and eventually becoming absorbed by the walls of the body lumen.
  • the reservoir is kept full while the medication is maintained under pressure, thereby continually providing medication to the reservoir as it is absorbed into the walls ofthe artery and as it leaks out around the edges ofthe collars.
  • the continued pressure applied to the medication additionally may gently force the medication into the walls ofthe tissue defining the body lumen. Any jetting that might occur, if higher than recommended pressure is applied to the inside ofthe balloon may be minimized since the pores are submerged in the annular reservoir and do not contact the arterial wall.
  • the collars tend to isolate the treated section ofthe body lumen by providing a substantial fluid seal in that area. Medication flow through the minute perforations can be maintained for up to several minutes to allow the medication a sufficient amount of time to penetrate the tissue to the extent desired without introducing large quantities ofthe medication into the patient's system. Withdrawal ofthe catheter is facilitated because the diameter ofthe central region is sufficiently large enough so that both shoulders will essentially simultaneously deflate under aspiration. It is therefore among the objects of the invention to provide an apparatus and method for local treatment of a body lumen or vessel with a high concentration of medication or drugs, without exposing other parts ofthe body to such high concentrations ofthe medication or drug.
  • FIG. 1 is a fragmented illustration ofthe balloon catheter used in the practice ofthe invention
  • Fig. 2 is an enlarged longitudinal cross-sectional illustration ofthe distal end and balloon ofthe catheter;
  • Fig. 2A is an enlarged cross-sectional illustration ofthe catheter shaft taken along line 2A-2A of Fig. 1 ;
  • Fig. 3 is an illustration ofthe balloon laid flat showing the locations ofthe holes as they may be formed by a laser;
  • Fig. 4 is a side view ofthe flattened balloon as seen from an end ofthe balloon;
  • Fig. 5 is a sectional illustration through the balloon illustrating the circumferential spacing ofthe rows of holes;
  • Fig. 6 is an illustration ofthe balloon in a deflated condition prior to insertion ofthe balloon into a patient's artery
  • Fig. 7 is an enlarged illustration ofthe balloon portion ofthe catheter in an artery and in an inflated configuration
  • Fig. 8 is an enlarged cross-sectional illustration ofthe boundary region ofthe balloon, fluid reservoir, and artery.
  • Fig. 1 illustrates the catheter used in the practice ofthe invention.
  • the catheter includes an elongated flexible shaft 10 that may be formed in an extrusion process from an appropriate polymeric material such as polyethylene.
  • the shaft 10 may be ofthe order of 150 cm long and may have an outer diameter of between 0.039 inches and 0.052 inches.
  • the catheter has a proximal end 12 and a distal end 14.
  • a bifurcate molding 13 is positioned near its proximal end to connect the lumens in the shaft 10 with separate proximal tubes 15, 17.
  • An inflatable and deflatable balloon, indicated generally at 16, is mounted on the distal end 14 ofthe catheter shaft 10. As shown in Figs.
  • the catheter shaft 10 includes an inflation lumen 18 that extends from the proximal end ofthe shaft 10 and terminates at an opening 20 within the balloon 16.
  • a fitting 22 on the proximal end of the tube 17 may be connected to a syringe (not shown) or other pressure fluid delivery device to enable inflation and deflation ofthe balloon.
  • the catheter shaft 10 also may be formed to include a guidewire lumen 26 that extends to and terminates in an outlet orifice 28 at the distal tip ofthe catheter shaft 10.
  • the guidewire lumen 26, accessible through a fitting 24 on the proximal tube 15, is receptive to a guidewire 27 by which the catheter may be guided through a patient's vasculature to the site to be treated.
  • a catheter shaft 10 having a diameter of about 0.044 inches may have a guidewire lumen 26 diameter of about 0.020 inches, and the inflation lumen 18 may have a maximum cross-sectional dimension of about 0.014 inches.
  • side-by-side parallel lumens are shown in the drawings, other two lumen structures may be used, including a coaxial lumen structure.
  • the balloon 16 is formed to have two collars 30 and a central region 31 between the collars 30.
  • the central region 31 may have a diameter of 2.0 millimeters while the collars 30 each may have a diameter of 2.5 millimeters, thus defining a thin, but distinct, annular reservoir about the central region when the balloon is inflated inside a body lumen.
  • the diameter ofthe central region 31 preferably is selected so that when inflated, it is spaced from the arterial wall to avoid or minimize any appreciable jetting effects against the arterial wall that may result from applying a pressure that is greater than the recommended maximum pressure for the catheter (about five bars).
  • the length ofthe balloon 16 may be varied depending upon the size ofthe region to be treated.
  • the central region 31 ofthe balloon 16 is provided with a plurality of minute holes 29 that may be substantially regularly spaced about the balloon 16 (see Fig. 3). For example, it has been found that an array of between ten and forty holes 29 (preferably about twenty), each having a diameter of about twenty-five microns will perform satisfactorily.
  • the holes 29 may be formed by a laser beam from an excimer laser having a wavelength of 248 or 308 nm. Holes so formed have been found to form clean edged holes 29 in the balloon material.
  • Figs. 2 and 3 illustrate a satisfactory pattern of holes 29 including four longitudinally extending rows having five holes in each row. Some ofthe rows may be staggered longitudinally with respect to each other.
  • the holes 29 are formed before the balloon 16 is attached to the catheter shaft 10.
  • the balloon 16 is laid flat, as shown in Figs. 3 and 4, while a laser beam is used to drill the holes 29 in the desired pattern.
  • the aggregate flow area defined by the holes 29 is selected so that under the general recommended range of inflation pressures expected (between about one to five bars), the liquid flow through the holes 29 will be relatively low and will not exceed a predetermined maximum flow rate.
  • the maximum flow rate should be selected so that the liquid will not jet through the holes 29.
  • the foregoing array of holes 29 has been found to produce satisfactorily low flow rates of fluid medications having a viscosity and fluid characteristic similar to saline (such as a heparin solution).
  • the maximum flow rate may be between 2 to 12 cc per minute under inflation pressures on the order of two to five atmospheres. Additionally, it is important that the holes 29 do not define a relatively large flow area that could adversely affect the rapidity with which the balloon 16 could be collapsed. Too large a flow area could compromise a physician's ability to withdraw the balloon 16 from the patient's vasculature. The flow area also must be small enough so that significant amounts of fluid will not flow from the balloon 16 prior to its being fully inflated.
  • the balloon 16 may be formed from various polymeric materials, such as polyethylene terephthalate, and preferably has a thin (0.001 inches or less), flexible, relatively inelastic wall.
  • the balloon 16 may be fabricated as described in U.S. Patent No. 4,490,421 (Levy) or European Patent Application No. 88300025 (Saab), published July 13, 1988 (European Publication No. 274411 ), now abandoned, the disclosures of which are incorporated by reference herein, in their entities.
  • a catheter adapted for use in the coronary arteries may have a balloon 16 that is about twenty millimeters or more long with a wall thickness of 0.001 inches or less. It is contemplated that with a relatively inelastic balloon 16, several different sizes of (inflated) balloons 16 may be required, depending upon the application in which the catheter is to be used.
  • Passive perfusion holes 33 may be formed in the catheter shaft in connection with the guidewire lumen 26, adjacent each end of the balloon 16, to provide a path for blood to flow through the catheter while the balloon is inflated. This enables a physician to prolong the medicine delivery procedure because blood flow through the artery is not unduly interrupted.
  • the guidewire 27 may be withdrawn from that portion of the guidewire lumen 26 (i.e. the area between the two perfusion holes 33) so that it does not impede blood flow through the lumen 26.
  • the catheter and practice ofthe method may be illustrated through its use as an adjunct to an arterial angioplasty procedure, such as percutaneous transluminal coronary angioplasty.
  • an arterial angioplasty procedure such as percutaneous transluminal coronary angioplasty.
  • the angioplasty procedure will have been performed by the physician according to any of a variety of techniques using various angioplasty catheters available.
  • the angioplasty procedure will have been performed either by a balloon catheter, laser catheter, atherectomy catheter, or other angioplasty catheter, that enlarges the lumen at the stenosed region ofthe artery to a nominal diameter of 2.5 mm.
  • the arterial wall may display a certain amount of recoil after the angioplasty so that the actual luminal diameter may be slightly smaller than 2.5 mm.
  • the angioplasty catheter In order thereafter to treat the arterial wall with concentrated heparin (or an isolated heparin fraction having anti-proliferative effect), the angioplasty catheter must be removed from the patient while the guidewire 27 remains in place.
  • the physician's assistant will have prepared the catheter ofthe present invention by filling the inflation lumen 18 and interior ofthe balloon 16 with a medication to purge the inflation lumen 18 and balloon 16 system of air.
  • the balloon 16 will then be wrapped about the catheter shaft and collapsed to a low profile, as suggested by Fig. 6, so that it may be passed through an indwelling guiding catheter.
  • the catheter 10 preferably is provided with one or more radiopaque marker bands by which the balloon 16 position may be monitored under fluoroscopy to verify placement ofthe balloon in the region to be treated.
  • the syringe or other inflation device is operated to pressurize the inflation lumen 18 and interior ofthe balloon 16 to cause the balloon 16 to inflate as suggested in Fig. 7.
  • the central region 31 ofthe balloon 16 will inflate into close proximity with the inner surface ofthe arterial lumen without actually contacting it, while the collars 30 will inflate into close pressing contact with the inner surface ofthe lumen to effect a substantial seal on each side ofthe central region.
  • Pressure is applied continually by the inflation device (which may be fitted with a pressure gauge) to maintain a substantially constant pressure level as desired, a range of pressures anticipated being ofthe order of one to five bars.
  • This pressure inflates the balloon 16 so that the collars 30 are firmly in contact with the luminal surface ofthe artery and the central region 31 is proximate to, but not contacting, the arterial wall.
  • a shallow annular reservoir 34 thus is defined between the balloon 16 and arterial wall. Medication will then flow through the holes 29 in the balloon 16 and fill the reservoir 34, consequently bathing the arterial wall. The pressure and flow will be continued for a predetermined time, for example one to several minutes, or enough time for the medicine to sufficiently penetrate into the arterial walls. It should be noted that since the contact between the collars 30 and the artery may tend to cause the artery to flex, and also since the inner surface ofthe artery usually is not uniformly smooth or circular, the collars 30 may not provide a perfect fluid seal for reservoir 34.
  • Blood that may be trapped in the reservoir 34 due to inflation ofthe balloon 16 should therefore migrate out ofthe reservoir 34, as will excess medication that flows from the balloon 16.
  • the balloon 16 is then deflated by aspirating through the inflation lumen 18 to cause the balloon 16 to collapse.
  • the selection ofthe number of holes 29 and their size should be made to prevent the aspiration of appreciable amounts of blood from the artery into the deflating balloon.
  • the flow area defined by the holes 29 is sufficiently minute and the balloon wall is sufficiently flexible so that the balloon 16 will readily collapse under aspiration.
  • the diameter of the central region 31 is sufficiently large enough so that the two collars 30 should deflate simultaneously at substantially the same rate.
  • the central region 31 ofthe balloon has a reduced diameter, there is less traumatic device contact with the arterial wall. If jetting should occur (when higher than recommended pressures are applied to the balloon), its effects may be avoided or minimized since the holes 29 are not in direct contact with the arterial walls. Accordingly, the invention is considered to provide a less traumatic localized medicine delivery than those catheters shown in the Wolinsky '244 patent. Moreover, the invention requires no more than two lumens and may have a lower profile than prior dual balloon devices. The invention is therefore capable of being used in smaller diameter arteries. Additionally, the diameter ofthe central region ofthe invention is selected so that both collars will deflate essentially simultaneously, thereby facilitating withdrawal ofthe catheter from the body lumen.
  • the invention by which highly concentrated medication may be applied to a surface of a body lumen, such as an artery, under sufficient pressure to cause the medication to penetrate into the tissue without introducing excessively high volumes of the medication into the patient's general system.
  • a body lumen such as an artery
  • the invention may be practiced in any instance where it is desired to apply a high concentration of medication to a local vessel or organ having a lumen accessible by a catheter.
  • the invention may be used to deliver chemotherapeutic drugs in the treatment of cancer patients where it is desired to apply concentrated medication for chemotherapeutic agents to the diseased organ.
  • the catheter may be passed into a lumen in the organ or may even be inserted into a lumen formed in the organ or tumor for the express purpose of receiving the catheter. Therefore, it should be understood that other embodiments, modifications and equivalents of the invention may be apparent to those skilled in the art without departing from its spirit.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Pulmonology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Anesthesiology (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Media Introduction/Drainage Providing Device (AREA)

Abstract

L'invention porte sur un procédé et l'appareil associé au moyen desquels un médicament fortement concentré ou un agent chimiothérapeutique peuvent être appliqués localement sous une pression suffisamment élevée pour leur permettre de pénétrer dans un tissu ciblé ou un orifice corporel. Le volume total de médicament ou d'agent est très faible et notablement inférieur aux doses susceptibles de provoquer une réaction adverse dans d'autres parties du corps. Le cathéter comporte un ballonnet souple à paroi mince comportant deux colliers et une zone centrale située entre les colliers et percée d'une série de perforations minuscules régulièrement espacés par lesquels le médicament peut suinter avec un débit donné très faible. La régulation du débit résulte de la taille des perforations, le diamètre de la région centrale étant inférieur à celui des colliers. Le ballonnet est choisi de manière à ce que le diamètre des colliers une fois gonflés soit égal ou légèrement supérieur à celui de la lumière où l'on place le ballonnet, et que celui de la zone centrale lui soit légèrement inférieur. On constitue ainsi un réservoir annulaire séparé de médicament entre le ballonnet et le corps de la lumière. L'épaisseur du réservoir réduit le risque de projection du médicament contre la lumière du vaisseau en cas de pression trop forte. Lorsqu'on gonfle le ballonnet à l'aide d'un médicament, ce dernier suinte de la zone centrale du ballonnet, remplit le réservoir et baigne les parois de la lumière. Après un temps donné, les parois de la lumière ayant absorbé une quantité suffisante de médicament, on dégonfle le ballonnet pour pouvoir extraire le cathéter de la lumière. La quantité de médicament passant finalement dans la lumière du vaisseau est suffisamment faible pour ne causer aucun autre dommage systémique au patient.
PCT/US1996/017434 1995-11-06 1996-10-29 Catheter a ballonnet pour l'application de medicaments WO1997017099A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US55397395A 1995-11-06 1995-11-06
US08/553,973 1995-11-06

Publications (1)

Publication Number Publication Date
WO1997017099A1 true WO1997017099A1 (fr) 1997-05-15

Family

ID=24211537

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US1996/017434 WO1997017099A1 (fr) 1995-11-06 1996-10-29 Catheter a ballonnet pour l'application de medicaments

Country Status (1)

Country Link
WO (1) WO1997017099A1 (fr)

Cited By (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999004845A3 (fr) * 1997-07-22 1999-04-15 Chase Medical Inc Catheter comprenant un ballonnet obstruant une lumiere et procede d'utilisation associe
US6607544B1 (en) 1994-01-26 2003-08-19 Kyphon Inc. Expandable preformed structures for deployment in interior body regions
US6719773B1 (en) 1998-06-01 2004-04-13 Kyphon Inc. Expandable structures for deployment in interior body regions
US6951555B1 (en) 1998-03-16 2005-10-04 Chase Medical, L.P. Catheter having integral expandable/collapsible lumen
US7147633B2 (en) 1999-06-02 2006-12-12 Boston Scientific Scimed, Inc. Method and apparatus for treatment of atrial fibrillation
US7211041B2 (en) 1999-05-07 2007-05-01 Boston Scientific Scimed, Inc. Apparatus and method for delivering therapeutic and diagnostic agents
US7261720B2 (en) 2002-01-11 2007-08-28 Kyphon Inc. Inflatable device for use in surgical protocol relating to fixation of bone
WO2009076732A1 (fr) 2007-12-17 2009-06-25 Brz Bio Tecnologia Ltda Cathéter pour la perfusion locale de médicaments
WO2012018899A1 (fr) * 2010-08-03 2012-02-09 Bayer Pharma Aktiengesellschaft Cathéter à ballonnet équipé d'un tube d'administration externe
WO2016070032A1 (fr) 2014-10-30 2016-05-06 Neurotronic, Inc. Ablation chimique et méthodes destinées à traiter diverses maladies
WO2016135716A1 (fr) 2015-02-26 2016-09-01 Jacob Schneiderman Procédés et compositions relatifs à des antagonistes de la leptine
US10537375B2 (en) 2015-04-24 2020-01-21 Neurotronic, Inc. Chemical ablation and method of treatment for various diseases
US11382689B2 (en) 2012-11-02 2022-07-12 Neurotronic, Inc. Chemical ablation formulations and methods of treatments for various diseases
CN119258371A (zh) * 2024-10-14 2025-01-07 普利瑞医疗科技（苏州）有限公司 一种药物球囊扩张导管及其使用方法
US12208224B2 (en) 2012-11-02 2025-01-28 Neurotronic, Inc. Chemical ablation and method of treatment for various diseases
CN120094075A (zh) * 2025-04-22 2025-06-06 新镜界(湘潭)医疗科技有限公司 一种可视肠梗阻导管套件

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5318531A (en) * 1991-06-11 1994-06-07 Cordis Corporation Infusion balloon catheter
EP0669143A1 (fr) * 1994-02-24 1995-08-30 Cardiovascular Dynamics, Inc. Cathéter à ballonnet pour dilatation avec diamétre variable

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5318531A (en) * 1991-06-11 1994-06-07 Cordis Corporation Infusion balloon catheter
EP0669143A1 (fr) * 1994-02-24 1995-08-30 Cardiovascular Dynamics, Inc. Cathéter à ballonnet pour dilatation avec diamétre variable

Cited By (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6607544B1 (en) 1994-01-26 2003-08-19 Kyphon Inc. Expandable preformed structures for deployment in interior body regions
US6979341B2 (en) 1994-01-26 2005-12-27 Kyphon Inc. Expandable preformed structures for deployment in interior body regions
US6045531A (en) * 1997-07-22 2000-04-04 Chase Medical Inc. Catheter having a lumen occluding balloon and method of use thereof
WO1999004845A3 (fr) * 1997-07-22 1999-04-15 Chase Medical Inc Catheter comprenant un ballonnet obstruant une lumiere et procede d'utilisation associe
US6951555B1 (en) 1998-03-16 2005-10-04 Chase Medical, L.P. Catheter having integral expandable/collapsible lumen
US7722624B2 (en) 1998-06-01 2010-05-25 Kyphon SÀRL Expandable structures for deployment in interior body regions
US6719773B1 (en) 1998-06-01 2004-04-13 Kyphon Inc. Expandable structures for deployment in interior body regions
US7875035B2 (en) 1998-06-01 2011-01-25 Kyphon Sarl Expandable structures for deployment in interior body regions
US7211041B2 (en) 1999-05-07 2007-05-01 Boston Scientific Scimed, Inc. Apparatus and method for delivering therapeutic and diagnostic agents
US7147633B2 (en) 1999-06-02 2006-12-12 Boston Scientific Scimed, Inc. Method and apparatus for treatment of atrial fibrillation
US7261720B2 (en) 2002-01-11 2007-08-28 Kyphon Inc. Inflatable device for use in surgical protocol relating to fixation of bone
WO2009076732A1 (fr) 2007-12-17 2009-06-25 Brz Bio Tecnologia Ltda Cathéter pour la perfusion locale de médicaments
EP2224990A4 (fr) * 2007-12-17 2012-03-28 Brz Biotecnologia Ltda Cathéter pour la perfusion locale de médicaments
US9005163B2 (en) 2010-08-03 2015-04-14 Bayer Pharma Aktiengesellschaft Balloon catheter with external delivery tube
WO2012018899A1 (fr) * 2010-08-03 2012-02-09 Bayer Pharma Aktiengesellschaft Cathéter à ballonnet équipé d'un tube d'administration externe
US11382689B2 (en) 2012-11-02 2022-07-12 Neurotronic, Inc. Chemical ablation formulations and methods of treatments for various diseases
US12208224B2 (en) 2012-11-02 2025-01-28 Neurotronic, Inc. Chemical ablation and method of treatment for various diseases
US12193731B2 (en) 2012-11-02 2025-01-14 Neurotronic, Inc. Chemical ablation formulations and methods of treatments for various diseases
US11684417B2 (en) 2012-11-02 2023-06-27 Neurotronic, Inc. Chemical ablation formulations and methods of treatments for various diseases
US11517725B2 (en) 2012-11-02 2022-12-06 Neurotronic, Inc. Chemical ablation and method of treatment for various diseases
EP3212274A4 (fr) * 2014-10-30 2018-06-27 Neurotronic, Inc. Ablation chimique et méthodes destinées à traiter diverses maladies
US10758713B2 (en) 2014-10-30 2020-09-01 Neurotronic, Inc. Chemical ablation and method of treatment for various diseases
US10286191B2 (en) 2014-10-30 2019-05-14 Neurotronic, Inc. Chemical ablation and method of treatment for various diseases
US11648378B2 (en) 2014-10-30 2023-05-16 Neurotronic, Inc. Chemical ablation and method of treatment for various diseases
CN107106820A (zh) * 2014-10-30 2017-08-29 纽敦力公司 治疗多种疾病的化学消融和方法
US12005207B2 (en) 2014-10-30 2024-06-11 Neurotronic, Inc. Chemical ablation and method of treatment for various diseases
WO2016070032A1 (fr) 2014-10-30 2016-05-06 Neurotronic, Inc. Ablation chimique et méthodes destinées à traiter diverses maladies
WO2016135716A1 (fr) 2015-02-26 2016-09-01 Jacob Schneiderman Procédés et compositions relatifs à des antagonistes de la leptine
US10537375B2 (en) 2015-04-24 2020-01-21 Neurotronic, Inc. Chemical ablation and method of treatment for various diseases
CN119258371A (zh) * 2024-10-14 2025-01-07 普利瑞医疗科技（苏州）有限公司 一种药物球囊扩张导管及其使用方法
CN120094075A (zh) * 2025-04-22 2025-06-06 新镜界(湘潭)医疗科技有限公司 一种可视肠梗阻导管套件

Similar Documents

Publication Publication Date Title
CA2008915C (fr) Catheter et methode pour l'application locale d'un medicament sur la paroi d'un vaisseau sanguin ou d'un autre organe creux
US5087244A (en) Catheter and method for locally applying medication to the wall of a blood vessel or other body lumen
EP0732958B1 (fr) Systéme intravasculaire pour l'administration de médicaments
US5021044A (en) Catheter for even distribution of therapeutic fluids
US5611775A (en) Method of delivery therapeutic or diagnostic liquid into tissue surrounding a body lumen
US8317747B2 (en) Catheter for tissue dilation and drug delivery
US5833658A (en) Catheters for the delivery of solutions and suspensions
EP1351738B1 (fr) Catheter d'administration de medicaments muni d'un ballonnet tres elastique perce de trous de perfusion
KR930002271B1 (ko) 혈관내 약품공급 확장 카테테르
US5464395A (en) Catheter for delivering therapeutic and/or diagnostic agents to the tissue surrounding a bodily passageway
US5336178A (en) Intravascular catheter with infusion array
US6129705A (en) Drug delivery and gene therapy delivery system
US5910101A (en) Device for loading and centering a vascular radiation therapy source
US5306250A (en) Method and apparatus for intravascular drug delivery
WO1997017099A1 (fr) Catheter a ballonnet pour l'application de medicaments
JP2001513374A (ja) バルーンカテーテルおよびその使用方法
JPH08187291A (ja) ポーラスバルーンカテーテル

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): JP

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): AT BE CH DE DK ES FI FR GB GR IE IT LU MC NL PT SE

121 Ep: the epo has been informed by wipo that ep was designated in this application
122 Ep: pct application non-entry in european phase